Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Avalo Therapeutics (AVTX) over the last 12 years, with Q3 2025 value amounting to -$15.3 million.

  • Avalo Therapeutics' Net Cash Flow fell 3235.88% to -$15.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$54.8 million, marking a year-over-year decrease of 17642.61%. This contributed to the annual value of $127.1 million for FY2024, which is 230247.79% up from last year.
  • Avalo Therapeutics' Net Cash Flow amounted to -$15.3 million in Q3 2025, which was down 3235.88% from -$82.7 million recorded in Q2 2025.
  • Over the past 5 years, Avalo Therapeutics' Net Cash Flow peaked at $102.8 million during Q1 2024, and registered a low of -$82.7 million during Q2 2025.
  • Over the past 5 years, Avalo Therapeutics' median Net Cash Flow value was -$3.9 million (recorded in 2022), while the average stood at $427000.0.
  • Per our database at Business Quant, Avalo Therapeutics' Net Cash Flow plummeted by 144451.01% in 2022 and then surged by 278425.48% in 2024.
  • Avalo Therapeutics' Net Cash Flow (Quarter) stood at -$17.0 million in 2021, then soared by 77.35% to -$3.9 million in 2022, then grew by 28.33% to -$2.8 million in 2023, then surged by 2003.11% to $52.6 million in 2024, then plummeted by 128.99% to -$15.3 million in 2025.
  • Its Net Cash Flow was -$15.3 million in Q3 2025, compared to -$82.7 million in Q2 2025 and -$9.5 million in Q1 2025.